Pharmaceutical

EC grants orphan medicinal product status to Rocket’s RP-A601

The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.

May 31, 2024 - 04:00
EC grants orphan medicinal product status to Rocket’s RP-A601
The EC has granted orphan medicinal product designation for Rocket Pharmaceuticals’ RP-A601 for PKP-2 related arrhythmogenic cardiomyopathy.
Read the original article

Tags:

Previous Article

AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs

Next Article

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bristol Myers Squibb’s Abecma recommended for EU approval

Bristol Myers Squibb’s Abecma recommended for EU approval

Jan 29, 2024

STAT+: Philips pays $2.4 million for allegedly giving kickbacks to sleep labs

STAT+: Philips pays $2.4 million for allegedly giving k...

Dec 27, 2023

STAT+: Winners and losers from Medicare’s list of drugs subject to price negotiation

STAT+: Winners and losers from Medicare’s list of drugs...

Aug 29, 2023